Article and Video CATEGORIES

Cancer Journey

Search By

Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?
Author
GRACE Videos and Articles

LCAM 2015

 

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

[powerpress]

Get more information about the ALEX Trial.

[ratingwidget post_id=0]

Check out more LCAM videos & posts here.

Next Previous link

Previous PostNext Post

Related Content

Online Community

Hi James Anthony, I'm so sorry you are going through this and so very young.  It' s true that some people benefit for years with chemo and targeted therapies.  With the...

Hi siigs, I'm sorry you're having health issues. They don't sound like pancoast tumor symptoms.  A consult with a pulmonologist can help to understand your chest symptoms and work toward alleviating...

Hi Lonnie, 

Yes, the info in last year's OncTalk was up to date at that moment.  I think it would be well worth the watch along with videos in our 2025...

Recent Comments

JOIN THE CONVERSATION
ROS 1
By JanineT GRACE … on
Hi siigs, I'm sorry you're…
By JanineT GRACE … on
Tomorrow Saturday, Oct. 25, 2025
By JanineT GRACE … on
Blood Cancers OncTalk-Live, Free, Learn Sat. Oct. 25
By JanineT GRACE … on